United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

21 Oct 2016
Change (% chg)

¥25 (+1.05%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for 4568.T


DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)


Beta: 0.86
Market Cap(Mil.): ¥1,687,802.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.52


  4568.T Industry Sector
P/E (TTM): 21.00 36.50 36.37
EPS (TTM): 113.34 -- --
ROI: 4.91 14.31 13.81
ROE: 6.33 15.13 14.76

BRIEF-Daiichi Sankyo Co Ltd, Dana-Farber Cancer Institute today announce lung cancer research collaboration

* Daiichi Sankyo Co Ltd - co, Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer

12 Oct 2016

BRIEF-Daiichi Sankyo begins enrollment for late-stage trial testing Quizartinib in leukemia patients

* Daiichi Sankyo Co Ltd - first patient has been enrolled in global phase 3 quantum-first study evaluating oral FLT3-ITD inhibitor quizartinib

11 Oct 2016

BRIEF-Daiichi Sankyo Co enters into a collaboration with Agonox Inc

* Daiichi Sankyo and Agonox will collaborate on preclinical development of program of an undisclosed immuno-oncology target

04 Oct 2016

BRIEF-Daiichi Sankyo announces New Global Head of Development

* Daiichi Sankyo announces new global head of development Source text for Eikon: Further company coverage:

06 Sep 2016

BRIEF-Daiichi Sankyo plans 5th&6th series unsecured corporate bonds worth total 100 bln yen

* Says it plans to issue 5th series unsecured corporate bonds worth 75 billion yen, with coupon rate of 0.810 percent and maturity date on July 25, 2036

15 Jul 2016

BRIEF-Amgen and Daiichi Sankyo agree to commercialize Biosimilars in Japan

* Amgen and daiichi sankyo announce agreement to commercialize biosimilars in japan

14 Jul 2016

REFILE-UCB receives approval for epilepsy drug Vimpat in Japan

July 4 Belgian pharmaceutical company UCB said on Monday it received regulatory approval for its epilepsy drug Vimpat in Japan.

04 Jul 2016

BRIEF-Daiichi Sankyo says entered into agreement with Servier Canada

* Daiichi Sankyo Co Ltd says has entered into an agreement with Servier Canada

27 Jun 2016

BRIEF-Daiichi Sankyo plans 28 mln shares repurchase

* Says it plans to buy 28 million shares (4.1 percent outstanding) back, for up to 500 million yen, from June 21 to Oct. 28

20 Jun 2016

BRIEF-Daiichi Sankyo to buy back up to 50 bln yen of stock

* Daiichi Sankyo says to buy back up to 4.1 percent of own shares worth 50 billion yen ($480 million) Source text for Eikon: Further company coverage: ($1 = 104.5400 yen)

20 Jun 2016

Earnings vs. Estimates